Has Margaret Scalia received payments from drug or device companies?

Yes. Drug and device makers reported $8,389 in general payments to Margaret Scalia across 289 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Margaret Scalia did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Margaret Scalia come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Margaret Scalia

Psychiatric/Mental Health · Danbury, CTNPI 1396009536

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 26.5% of the total. Among psychiatric/mental health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,389in general payments, 2019–2025

Across 289 payments — averaging $29.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Otsuka America Pharmaceutical, Inc.$1K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$927
Neurocrine Biosciences, Inc.$691
Teva Pharmaceuticals USA, Inc.$561
Alkermes, Inc.$379
plus $2K from 23 others

What the payments were for

Food & beverage$8,34099%
Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	113	$2,225
Otsuka America Pharmaceutical, Inc.	34	$1,360
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	19	$927
Neurocrine Biosciences, Inc.	12	$691
Teva Pharmaceuticals USA, Inc.	6	$561
Alkermes, Inc.	12	$379
Corium, LLC	20	$336
Axsome Therapeutics, Inc.	12	$334
Ironshore Pharmaceuticals Inc.	4	$211
Avanir Pharmaceuticals, Inc.	4	$206
Johnson & Johnson	6	$158
Otsuka Pharmaceutical Development & Commercialization, Inc.	4	$123
Bausch Health US, LLC	5	$97
Supernus Pharmaceuticals, Inc.	5	$85
Tempus AI, Inc	4	$84
Lundbeck LLC	3	$83
Tris Pharma Inc	4	$81
Boehringer Ingelheim	2	$69
Idorsia Pharmaceuticals US Inc	3	$59
Sunovion Pharmaceuticals Inc.	3	$51
Almatica Pharma LLC	2	$47
E.r. Squibb & Sons, L.L.C.	2	$44
Arbor Pharmaceuticals, Inc.	2	$37
Vanda Pharmaceuticals Inc.	2	$37
Takeda Pharmaceuticals U.S.A., Inc.	2	$35
Vertical Pharmaceuticals, LLC	1	$21
Merck	1	$20
Jazz Pharmaceuticals Inc.	1	$16
Adlon Therapeutics L.p.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,389 in reported general payments places this provider in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Aripiprazole	24	$762
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	12	$585
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	17	$340
Lorazepam	38	$172
Bupropion XlBupropion Hcl	12	$158
Lamotrigine	16	$155
Duloxetine Hcl	27	$150
Gabapentin	15	$141
Venlafaxine Hcl ErVenlafaxine Hcl	14	$140
Alprazolam	34	$95
Paroxetine Hcl	12	$54
Quetiapine Fumarate	17	$19
Sertraline Hcl	13	$14
Zolpidem Tartrate	14	$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Almatica Pharma LLCSertraline Hcl	$47	$1413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.

Other psychiatric/mental health in Danbury

Donna DraperDanbury$19K
Zahida SairitupaDanbury$19K
Gregory GuionDanbury$6K
Allison HayesDanbury$4K
Cristina MeehanNew Britain$224K
Samantha MrazBridgeport$87K
Philip FrickManchester$31K
Gia SantoroWest Haven$25K
Hui HuNorwich$19K
Patrick GagnonMilford$15K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →